Home › Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
 

Keywords :   


Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For Revusiran, An Investigational RNAi Therapeutic For The Treatment Of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

2015-06-03 06:41:56| drugdiscoveryonline Home Page

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to revusiran, an investigational RNAi therapeutic, for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)

Tags: united states united states food

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.10Hurricane Milton Public Advisory Number 11A
08.10Summary for Hurricane Milton (AT4/AL142024)
08.10Eastern North Pacific Tropical Weather Outlook
08.10Atlantic Tropical Weather Outlook
08.10Wait longer for an electric taxi, says Uber boss
07.10Hurricane Milton Probabilistic Storm Surge Graphics
07.10Customers of failed crypto firm FTX set for refunds
07.10Hurricane Milton Graphics
More »